Now I have all the information I need. Let me write the consolidated review.

## Summary

This paper proposes Active Probabilistic Drug Discovery (APDD), a method that combines probabilistic molecule clustering (via MPC), selective docking (VinaGPU+), and an active learning query strategy to reduce the computational and wet-lab costs of early drug discovery. The method is evaluated on 90 targets from DUD-E and LIT-PCBA, as well as a simulated million-scale library. The paper claims an average 80% reduction in docking expenses and 70% reduction in wet-lab experiments while maintaining comparable accuracy.

## Strengths

- **Large-scale empirical validation**: The method is evaluated across 90 targets (79 from DUD-E, 11 from LIT-PCBA), which is a substantial benchmark scope appropriate for drug discovery. This breadth lends weight to the statistical claims.

- **Validation of the clustering assumption**: Table 3 provides a direct empirical check of the paper's core premise — that active molecules are not uniformly distributed but concentrated in small, pure clusters (cluster size ≤8, cumulative active ratio ≥0.9). This analysis is concrete and supports the motivation for cluster-based prioritization.

- **Scalability demonstrated on million-scale libraries**: Table 4 tests APDD on datasets augmented to 1.4M molecules and shows that APDD recovers the target number of actives with approximately 20% of the docking and wet-lab costs of full Vina Enumeration. This experiment also explicitly tabulates the VE baseline alongside APDD, unlike the main results.

- **Principled active refinement in a no-retraining setting**: The query strategy (Section 4.3) is designed for the realistic constraint that limited wet-lab data prohibits model retraining. The cluster-based and molecule-based variants for expected recall improvement are a concrete algorithmic adaptation to this constraint, distinguishing APDD from typical active-learning approaches that assume abundant feedback.

## Weaknesses

### Major

- **Baseline (VE) numbers are not tabulated in the main results tables.** The paper's central quantitative claim — 82%/75% cost reductions on DUD-E and 85%/40% on LIT-PCBA — cannot be verified from the data presented. Tables 1–3 report APDD's docking and wet-lab counts but do not show VE's docking or wet-lab counts for the same targets at the same recall level. Without these numbers, the reader cannot compute the claimed reductions, assess per-target variance, or determine whether savings come from the method itself or from the properties of the baseline. This is the single most consequential weakness: the paper's main empirical contribution is presented in a format that does not support verification. (Table 4 does include the VE comparison for the large-scale experiment, but this does not compensate for its absence in the principal DUD-E/LIT-PCBA results.)

- **The stopping criterion is underspecified.** The paper states: "We terminate the APDD cycle when the recall rate of the top 100 molecules reaches the target recall rate." The "target recall rate" is never defined numerically. Both APDD and VE are apparently run to this same undefined target, which makes the comparison internally consistent, but it prevents the reader from interpreting the absolute cost numbers or comparing the method to other work. Additionally, the paper claims "comparable screening accuracy" but reports no explicit accuracy metric (enrichment factor, ROC AUC, hit rate) — only the cost reductions at the matched recall target. The accuracy claim therefore rests entirely on the matched-recall design, which should be stated more clearly.

### Minor

- **The active learning component is not isolated by ablation.** The paper does not compare its query strategy (maximizing expected recall improvement) against simpler alternatives such as random selection within top clusters, greedy selection by docking score, or uniform random sampling. Because the clustering already concentrates actives, the added value of the specific acquisition function is unclear. The paper dismisses ML-based AL methods as requiring too many wet experiments for retraining, which is a valid justification for excluding them, but it does not test the simpler non-ML baselines that would isolate the contribution of the query strategy itself.

- **The Tanimoto-similarity-as-binding-probability claim is stated without shown validation.** Equation (1) defines pairwise binding probability as Tanimoto similarity of Morgan fingerprints. The paper says this is "further validated using statistics from Lit-PCBA/DUD-E/PubChem datasets" but presents no such analysis. While Tanimoto similarity is a standard measure of molecular similarity and the assumption that structurally similar molecules tend to bind the same target is widely accepted in ligand-based virtual screening, the paper frames this as a validated probability estimate without providing evidence. At minimum, a correlation analysis or calibration plot should have been included.

- **Overclaiming in the conclusion.** The final sentence states: "Our proposed paradigm aims to eliminate the need for lead optimization by significantly expanding the size of virtual molecule libraries." Nothing in the paper tests or supports this claim — the experiments are about screening hit identification, not about eliminating downstream optimization. This overreach undercuts the otherwise reasonable presentation.

### Trivial

- None that survive filtering.

## Nice-to-Haves

- Reporting AUC or enrichment factor for the docking scores on each target would help the reader assess the difficulty of each screening task and contextualize the cost savings.
- A recall-vs-budget curve for a representative set of targets would make the APDD advantage visually interpretable.

## Removed Points

- **Criticism that the evaluation protocol is "circular"** — this is not supported by the paper; the protocol is simply underspecified. The matched-recall comparison is a valid design.
- **Criticism that the formulation is "not mathematically formalized"** — this is scope creep for an applied systems paper that describes an algorithmic pipeline.
- **Criticism that MPC is treated as a black box** — using an existing clustering algorithm as a component is standard practice.
- **Criticism about generic motivation/broad introduction** — this is a style preference, not a substantive weakness.
- **Complaints about missing appendix content or formatting artifacts** — parser artifacts or content stripped by the review format.
- **Strength Finder strength #1 as written** — claimed that Table 2 "directly validates" the cost savings, but the missing baseline comparison makes this claim unsupported. The strength is reframed above as scale (90 targets) rather than validated savings.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface a genuinely novel observation that the authors missed.

## Suggestions

1. **Add a table that directly compares APDD vs. VE for every target**: columns for APDD docking count, APDD wet-lab count, VE docking count, VE wet-lab count, total molecule count, and the target recall used. This single table would address the most significant weakness.
2. **Define the target recall rate explicitly** in the experimental setup, and add a brief sentence explaining why this value was chosen.
3. **Add an ablation** comparing APDD's full query strategy against (a) random selection within top clusters and (b) greedy selection by docking score, keeping the clustering fixed.
4. **Include the Tanimoto-validation analysis** or, if it was omitted for space, note that a small-scale correlation analysis was performed and summarize the result.
5. **Remove or substantially qualify** the unsupported claim about eliminating lead optimization.

## Score and Decision

### Calibration Anchors

| Anchor | Avg Score | Comparison |
|--------|-----------|------------|
| GNNAS-Dock (An87ZnPbkT.md) | 3.00 | Has severe methodological flaws (data leakage, no generalization). Current paper is clearly stronger in methodology and evaluation design. |
| Molecular Active Learning (kYg04pmX7i.md) | 4.40 | Also has missing comparisons and scope questions, but is well-written and asks a clear research question. Comparable in overall quality — both have genuine contributions undermined by evaluation gaps. |
| DockedAC (HBbbhAZuia.md) | 5.75 | Well-executed dataset contribution with thorough benchmarks. Current paper has a stronger algorithmic contribution but weaker, less transparent evaluation. |
| Redefining Bioactivity (S8gbnkCgxZ.md) | 7.00 | Strong problem reframing with clear evaluation and large-scale dataset. Current paper is notably weaker in evaluation clarity and experimental rigor. |
| FlexDock (gHLWTzKiZV.md) | 8.00 | Strong theoretical contribution (Unbalanced Flow Matching) with thorough experiments and ablations. Current paper is much weaker in both theoretical depth and experimental execution. |

The paper has a practical, well-motivated approach and a reasonable experimental scope (90 targets). However, the central quantitative claim is presented in a form that prevents verification — the baseline comparison is not tabulated in the main results, and the stopping criterion is underspecified. These are not fatal (the method could be sound), but they are material gaps that prevent the paper from supporting its headline claims in its current form. The paper falls between the flawed-low range (∼3.0) and the solid-medium range (∼5.75); it is meaningfully stronger than the former but has more significant evaluation gaps than the latter.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>